Following the documentation of a case of Bell's palsy associated with vaccination,1 we were contacted by patients and colleagues from Canada, Australia, Europe, the UK, and United Arab Emirates. Questions raised were whether mRNA vaccine recipients are at increased risk of developing Bell's palsy, and what to recommend to individuals with a history of Bell's palsy.
In their Comment, Al Ozonoff and colleagues2 considered key statistical and epidemiological aspects of SARS-CoV-2 vaccine trial safety data regarding the onset of facial paralysis. Here, we offer a different interpretation of their findings and statistical consideration of risks associated with mRNA and non-mRNA SARS-CoV-2 vaccines.
Comments